AstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy

AstraZeneca Plc said it is withdrawing an application for European approval for an ovarian-cancer medicine following disagreement with regulatory authorities.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.